Mehta Kishan 4
4 · Benitec Biopharma Inc. · Filed Dec 11, 2024
Insider Transaction Report
Form 4
Mehta Kishan
Director
Transactions
- Award
Options (right to buy)
2024-12-09+35,000→ 35,000 totalExercise: $12.18Exp: 2034-12-09→ Common Stock (35,000 underlying)
Footnotes (2)
- [F1]Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Mehta in connection with his role as a member of the Issuer's Board of Directors. Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds") is holding such options for the benefit of the Funds, and as such Mr. Mehta disclaims beneficial ownership of such options. The Funds, and Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Mehta's board service.
- [F2]The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 9, 2025.